RAF1 and neoplasm: Sorafenib is a multikinase inhibitor (4) that exerts its antitumor effects through two primary mechanisms: it inhibits the Ras/Raf/MEK/ERK signaling pathway by targeting Raf-1 and B-Raf, thereby suppressing tumor cell proliferation, and it blocks angiogenesis by targeting receptor tyrosine kinases such as PDGFR-β and VEGFR (5).